Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Merck
Teva
Queensland Health
Chinese Patent Office
Accenture
Argus Health
Fish and Richardson
Express Scripts

Generated: January 18, 2018

DrugPatentWatch Database Preview

DARIFENACIN HYDROBROMIDE Drug Profile

« Back to Dashboard

When do Darifenacin Hydrobromide patents expire, and what generic alternatives are available?

Darifenacin Hydrobromide is a drug marketed by Anchen Pharms, Aurobindo Pharma Ltd, Cipla Ltd, Jubilant Generics, and Torrent Pharms Ltd. and is included in five NDAs.

The generic ingredient in DARIFENACIN HYDROBROMIDE is darifenacin hydrobromide. There are nineteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the darifenacin hydrobromide profile page.
Summary for DARIFENACIN HYDROBROMIDE
Drug patent expirations by year for DARIFENACIN HYDROBROMIDE
Pharmacology for DARIFENACIN HYDROBROMIDE

US Patents and Regulatory Information for DARIFENACIN HYDROBROMIDE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Anchen Pharms DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 091190-001 Mar 13, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Jubilant Generics DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205550-001 Oct 12, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 206743-002 Sep 19, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Jubilant Generics DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205550-002 Oct 12, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Anchen Pharms DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 091190-002 Mar 13, 2015 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Aurobindo Pharma Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 206743-001 Sep 19, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Cipla Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207664-002 Sep 1, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Cipla Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 207664-001 Sep 1, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Torrent Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205209-002 Nov 17, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Torrent Pharms Ltd DARIFENACIN HYDROBROMIDE darifenacin hydrobromide TABLET, EXTENDED RELEASE;ORAL 205209-001 Nov 17, 2016 AB RX No No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Cipla
Argus Health
Julphar
Cerilliant
Chubb
Teva
Baxter
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot